Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miravirsen + telaprevir + ribavirin
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
This is a combination of **miravirsen** (an antisense oligonucleotide directed against microRNA-122), **telaprevir** (a direct-acting antiviral targeting the hepatitis C virus NS3/4A serine protease), and **ribavirin** (a nucleoside analogue antiviral) developed for the treatment of chronic hepatitis C virus (HCV) infection, particularly in patients who have failed prior therapy with pegylated interferon and ribavirin. Miravirsen exerts its effect by binding to and sequestering miR-122, a liver-specific microRNA required for HCV replication, thus suppressing viral replication. Telaprevir inhibits the viral NS3/4A protease, blocking polyprotein processing and viral replication. Ribavirin is a broad-spectrum antiviral with multiple proposed mechanisms, including inhibition of viral RNA synthesis. The combination aims to improve outcomes in difficult-to-treat patients, especially null responders, by targeting different stages of the viral life cycle and the viral host requirement[5][6][3].
- Other names
- miravirsen + telaprevir + ribavirin
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)SLC47A1 (Multidrug and toxin extrusion transporter 1)OCT2 (Organic cation transporter 2)
Beyond the preview
Go deeper on miravirsen + telaprevir + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miravirsen + telaprevir + ribavirin.